Mifegyne (Mifepristone)

Mifepristone works by binding competitively to progesterone receptors in the uterus, blocking progesterone’s action. This causes the decidua to break down, the gestational sac to detach, and uterine contractility to increase, leading to termination of pregnancy. It also blocks glucocorticoid receptors when used for Cushing’s syndrome.

The exact dose of Mifegyne is determined by the prescribing clinician based on the indication, gestational age and local guidelines. Typically a single oral tablet is administered, often followed by misoprostol, but the prescriber sets the regimen and timing.

Mifegyne is contraindicated in an ongoing pregnancy beyond the approved gestational window and should not be used during breastfeeding without medical supervision. Women are advised to avoid breastfeeding until the drug is cleared from their system, as safety data are limited.

To order Mifegyne, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

The most common alternative for early medical abortion is methotrexate, which works by inhibiting cell division. Mifepristone directly blocks progesterone receptors, leading to a faster and more predictable abortion process when combined with misoprostol, whereas methotrexate requires a longer treatment period and has a different side‑effect profile.

Mifegyne tablets should be stored at ambient temperature, below 25 °C, in their original blister pack or container. Protect them from moisture and direct sunlight. Keep out of reach of children and do not use if the packaging is damaged.

Mifegyne is taken as an oral tablet. The tablet should be swallowed whole with a glass of water; it should not be chewed, crushed or split. Administration is usually performed in a clinical setting under medical supervision.

Serious risks include heavy hemorrhage requiring medical intervention, severe infection or sepsis, and allergic reactions such as rash, swelling or anaphylaxis. Patients should seek immediate medical attention if they experience excessive bleeding, fever, severe abdominal pain or signs of an allergic response.

Mifegyne should not be used in women with confirmed or suspected ectopic pregnancy, chronic adrenal insufficiency, severe anemia, uncontrolled bleeding disorders, or those taking anticoagulant therapy without careful monitoring. It is also contraindicated in individuals with known hypersensitivity to mifepristone.